A new, pooled analysis of data from Novo Nordisk’s Phase III trials SUSTAIN 6 and PIONEER 6 shows that semaglutide may help patients with type 2 diabetes live longer without a cardiovascular event. PharmaTimes talks to lead study investigator Dr Jan Westerink about the importance of these findings
Will COVID help accelerate a more personalised approach to medicine?
What 2020 has taught the pharma industry about the necessity of transforming regulatory information management
Accelerating innovation and its impact on patients and sites
Jenny Ousbey outlines the patient experience and developments in advocacy
As mega deals slow, private capital becomes the driving force behind 2020 M&A
Oli Hudson explores the changes that have occurred in the NHS this year as the Long Term Plan has been rolled out at speed in response to the COVID crisis
Leslie Galloway looks back over 2020, outlining the challenges faced by the life sciences sector and the potential opportunities that lie ahead
